Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
IPO Year: 2006
Exchange: NASDAQ
Website: vandapharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2025 | $11.00 | Buy | B. Riley Securities |
| 10/31/2024 | $18.00 | Buy | H.C. Wainwright |
| 7/11/2024 | $11.00 | Overweight | Cantor Fitzgerald |
| 2/25/2022 | $24.00 → $12.00 | Buy → Hold | Jefferies |
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling
Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling
Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
S-3 - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
10-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
SCHEDULE 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
B. Riley Securities initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $11.00
H.C. Wainwright initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00
Cantor Fitzgerald initiated coverage of Vanda Pharma with a rating of Overweight and set a new price target of $11.00
Jefferies downgraded Vanda Pharmaceuticals from Buy to Hold and set a new price target of $12.00 from $24.00 previously
B of A Securities initiated coverage of Vanda Pharmaceuticals with a rating of Buy and set a new price target of $22.00
Citigroup reiterated coverage of Vanda Pharmaceuticals with a rating of and set a new price target of $18.00 from $14.00 previously
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
Fastest customizable press release news feed in the world
WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the company will participate in the 2026 Citizens Life Sciences Conference in Miami on Wednesday, March 11, 2026. A corporate presentation is scheduled for 2:15 p.m. Eastern Time. The corporate presentation given at the Citizens Life Sciences Conference may be accessed live on Vanda's corporate website, www.vandapharma.com. Investors should click on the Investors tab and follow the link under Recent Events. Investors are advised to go to the conference website at least
WASHINGTON, Feb. 25, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), with a target action date of December 12, 2026. GPP is a rare, chronic, life-threatening autoinflammatory skin disorder characterized by sudden flares of widespread pustules, erythema, and systemic symptoms such as fever and fatigue. The pathogenesis of GPP is increasingly understood th
WASHINGTON, Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a first line therapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults. BYSANTI™ is a new chemical entity (NCE) that belongs in the class of atypical antipsychotics. In clinical studies BYSANTI™ demonstrated bioequivalence to iloperidone across the therapeutic dosing spectrum enabling it to leverage well
Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motionBysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026WASHINGTON, Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.
Conference Call and Webcast to Follow WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2025 on Wednesday, February 11, 2026, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, February 11, 2026, during which management will discuss the fourth quarter and full year 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international
WASHINGTON, Jan. 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it has received a decision letter from the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) concluding that the supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) for the treatment of jet lag disorder cannot be approved in its current form. This letter stems from CDER's agreed re-review of the jet lag application under the October 1 collaborative framework agreement. The FDA acknowledged positive efficacy from V
WASHINGTON, Dec. 30, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion. This approval marks the first new pharmacologic treatment in motion sickness in over four decades, representing a significant advancement in the understanding and management of this debilitating physiologic response that affects a substantial portion of the population and has long been recognized as a factor affecting military operational readiness.
WASHINGTON, Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP). Imsidolimab inhibits IL-36 receptor signaling, addressing the deficiency in the endogenous IL-36RA regulator commonly seen in GPP patients due to IL36RN gene mutations. The BLA is supported by positive results from the global Phase 3 GEMINI-1 and GEMINI-2 studies, wher
WASHINGTON, Dec. 11, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 15, 2026. A corporate presentation is scheduled for 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time). The corporate presentation given at the J.P. Morgan Healthcare Conference may be accessed live on Vanda's corporate website, www.vandapharma.com. Investors should click on the Investors tab and follow the link under Recent Events. Investors are adv
WASHINGTON, Dec. 4, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on protocol VP-VLY-686-3403, which until today limited the protocol to a maximum of 90 doses of tradipitant. The lift followed Vanda's formal dispute resolution request and an expedited re-review conducted by CDER leadership under the collaborative framework established between Vanda and the FDA in October 2025. The FDA agreed with Vanda's position that motion sickness is an acute, self-limiting
Live Leadership Updates
WASHINGTON, March 17, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective March 15, 2023. Following Dr. Honoré's appointment, Vanda's Board of Directors is now comprised of six directors, five of whom are independent. "Tage is a highly accomplished industry leader and respected scientist with deep experience across a diverse range of therapeutic areas," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "We are confident that his scientific expertise and executive experience will be invaluable, and look forward to working with him as we contin
Live finance-specific insights
Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motionBysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026WASHINGTON, Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.
Conference Call and Webcast to Follow WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2025 on Wednesday, February 11, 2026, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, February 11, 2026, during which management will discuss the fourth quarter and full year 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international
Fanapt® Q3 2025 net product sales increased by 31% to $31.2 million compared to Q3 2024BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness under review by the FDA; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in Q4 2025Vanda announced collaborative framework with the FDA for resolution of certain disputesRe-review of Vanda's sNDA for HETLIOZ® for the treatment of jet lag disorder by January 7, 2026WASHINGTON, Oct. 29, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today an
Conference Call and Webcast to Follow WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2025 on Wednesday, October 29, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, October 29, 2025, during which management will discuss the third quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international) and use passcode 8728050. The
Fanapt® Q2 2025 net product sales increased by 27% to $29.3 million compared to Q2 2024Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025WASHINGTON, July 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2025.
Conference Call and Webcast to Follow WASHINGTON, July 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the second quarter 2025 on Thursday, July 31, 2025, before the market opens. Vanda will host a conference call at 8:00 AM ET on Thursday, July 31, 2025, during which management will discuss the second quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 9430387. The conf
Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025WASHINGTON, May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has entered a new g
Conference Call and Webcast to Follow WASHINGTON, May 2, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the first quarter 2025 on Wednesday, May 7, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, May 7, 2025, during which management will discuss the first quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 9941754. The conference
Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023Full year 2024 total revenues of $198.8 million, +3% compared to full year 2023Full year 2025 revenue expected to grow to $210 to $250 millionPsychiatry portfolio revenue expected to grow to greater than $750 million in 2030Fanapt® MAA for bipolar I disorder and schizophrenia submitted in Q4 2024BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia expected to be submitted in Q1 2025HETLIOZ® MAA for Smith-Magenis syndrome submitted in Q4 2024Tradipitant NDA for motion sickness submitted in Q4 2024Imsidolimab BLA in generalized pustular
Conference Call and Webcast to Follow WASHINGTON, Feb. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2024 on Thursday, February 13, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Thursday, February 13, 2025, during which management will discuss the fourth quarter and full year 2024 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international
This live feed shows all institutional transactions in real time.
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)